Bioneedles as alternative delivery system for hepatitis B vaccine

被引：35

作者：

Hirschberg, Hoang J. H. B. ^{[1
]}

de Wijdeven, Gijsbert G. P. van ^{[2
]}

Kraan, Heleen ^{[1
]}

Amorij, Jean-Pierre ^{[1
]}

Kersten, Gideon F. A. ^{[1
]}

机构：

[1] Netherlands Vaccine Inst, Unit R&D, Bilthoven, Netherlands

[2] Bioneedle Technol Grp BV, Eindhoven, Netherlands

来源：

JOURNAL OF CONTROLLED RELEASE | 2010年 / 147卷 / 02期

关键词：

Hepatitis B surface antigen; Bioneedle; Freeze drying; Stability; Adjuvant; Formulation; SURFACE-ANTIGEN; IMMUNOGENICITY; PREVALENCE; STABILITY; PAIN; FEAR;

D O I：

10.1016/j.jconrel.2010.06.028

中图分类号：

O6 [化学];

学科分类号：

070301 [无机化学];

摘要：

An alternative vaccine delivery system for needle injections is the Bioneedle. Hepatitis B surface antigen (HBsAg) was formulated with Bioneedles. Three formulations were used: plain antigen. HBsAg adjuvated with aluminum hydroxide and HBsAg with LPS-derived IpxL1. Bioneedles with HBsAg-IpxL1 were the most stable and the most immunogenic formulations. The conventional liquid alum adjuvated vaccine lost 40% of its antigenicity after 1 week at 50 degrees C whereas the HBsAg-IpxL1 Bioneedles showed no significant decrease after 3 weeks at 50 degrees C. in vivo studies revealed that the HBsAg-IpxL1 Bioneedle formulations induced comparable IgG titers as conventional liquid formulations after 2 immunizations, but higher IgG2a titers were found already after 1 immunization. The in vivo and in vitro studies showed that the Bioneedle is an attractive alternative for needle injections of HBsAg vaccines. (C) 2010 Elsevier B.V. All rights reserved.

引用

页码：211 / 217

页数：7

共 32 条

[1]

Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives [J].

Arigita, C ;

Luijkx, T ;

Jiskoot, W ;

Poelen, M ;

Hennink, WE ;

Crommelin, DJA ;

van der Ley, P ;

van Els, C ;

Kersten, GFA .

VACCINE, 2005, 23 (43) :5091-5098

[2]

Micro-scale devices for transdermal drug delivery [J].

Arora, Anubhav ;

Prausnitz, Mark R. ;

Mitragotri, Samir .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 364 (02) :227-236

[3]

Oral vaccines: new needs, new possibilities [J].

Aziz, Mohd Azhar ;

Midha, Shuchi ;

Waheed, Syed Mohsin ;

Bhatnagar, Rakesh .

BIOESSAYS, 2007, 29 (06) :591-604

[4]

Implementing the birth dose of hepatitis B vaccine in rural Indonesia [J].

Creati, Mick ;

Saleh, Asmaniar ;

Ruff, Tilman A. ;

Stewart, Tony ;

Otto, Bradley ;

Sutanto, Agustinus ;

Clements, C. John .

VACCINE, 2007, 25 (32) :5985-5993

[5]

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity [J].

de Vries, J. J. C. ;

Bungener, L. ;

ter Veer, W. ;

van Alphen, L. ;

van der Ley, R. ;

Wilschut, J. ;

Huckriede, A. .

VACCINE, 2009, 27 (06) :947-955

[6]

Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles [J].

Diminsky, D ;

Moav, N ;

Gorecki, M ;

Barenholz, Y .

VACCINE, 1999, 18 (1-2) :3-17

[7]

Can drug-bearing liposomes penetrate intact skin? [J].

El Maghraby, GMM ;

Williams, AC ;

Barry, BW .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2006, 58 (04) :415-429

[8]

Galazka A., 1998, THERMOSTABILITY VACC

[9]

Needle-free vaccine delivery [J].

Giudice, EL ;

Campbell, JD .

ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (01) :68-89

[10]

THERMAL-STABILITY OF HEPATITIS-B SURFACE ANTIGEN-S PROTEINS [J].

GOMEZGUTIERREZ, J ;

RODRIGUEZCRESPO, I ;

GONZALEZROS, JM ;

FERRAGUT, JA ;

PAUL, DA ;

PETERSON, DL ;

GAVILANES, F .

BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1119 (03) :225-231

← 1 2 3 4 →